Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil
| Autor: | A.M. Nishikawa, Luciano Paladini, C.C. Bueno, Otavio Clark, A.L. Liamas |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Cost effectiveness Multiple sclerosis Health Policy Interferon beta-1a Public Health Environmental and Occupational Health medicine.disease Natalizumab Relapsing remitting Internal medicine Immunology Medicine Line (text file) business medicine.drug |
| Zdroj: | Value in Health. 16(7):A721-A722 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2013.08.2249 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect